Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Osi-632. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 10/20 | 0.98 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.98 |
| ▸ | FLT1 | P17948 | 6/20 | 0.98 |
| ▸ | PLK4 | O00444 | 1/20 | 0.98 |
| ▸ | AURKA | O14965 | 1/20 | 0.98 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.98 |
| ▸ | STK10 | O94804 | 1/20 | 0.98 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.98 |
| ▸ | ABL1 | P00519 | 1/20 | 0.98 |
| ▸ | EGFR | P00533 | 1/20 | 0.98 |
| ▸ | INSR | P06213 | 1/20 | 0.98 |
| ▸ | LCK | P06239 | 1/20 | 0.98 |
| ▸ | FYN | P06241 | 1/20 | 0.98 |
| ▸ | YES1 | P07947 | 1/20 | 0.98 |
| ▸ | LYN | P07948 | 1/20 | 0.98 |
| ▸ | RET | P07949 | 1/20 | 0.98 |
| ▸ | MET | P08581 | 1/20 | 0.98 |
| ▸ | ROS1 | P08922 | 1/20 | 0.98 |
| ▸ | BCR | P11274 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Osi-632 SCHEMBL187261 | 0.99 | KDR (1.00) | KDRPDGFRBFLT1PLK4AURKA | |
| Osi-632 SCHEMBL5705524 | 0.98 | KDR (0.98) | KDRPDGFRBFLT1PLK4AURKA | |
| Osi-632 SCHEMBL5705560 | 0.96 | KDR (0.94) | KDRPDGFRBFLT1PLK4AURKA | |
| Osi-632 SCHEMBL5705534 | 0.96 | KDR (0.94) | KDRPDGFRBFLT1PLK4AURKA | |
| Osi-632 SCHEMBL5705655 | 0.94 | KDR (0.90) | KDRPDGFRBFLT1PLK4AURKA | |
| SCHEMBL3083706 | 0.93 | KDR (0.88) | KDRPDGFRBFLT1PLK4AURKA | |
| SCHEMBL3085641 | 0.92 | KDR (0.87) | KDRPDGFRBFLT1PLK4AURKA | |
| SCHEMBL3084090 | 0.92 | KDR (0.87) | KDRPDGFRBFLT1PLK4AURKA | |
| Osi-632 SCHEMBL6380035 | 0.92 | KDR (0.86) | KDRPDGFRBFLT1PLK4AURKA | |
| SCHEMBL1786207 | 0.92 | KDR (0.86) | KDRPDGFRBFLT1PLK4AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170173161-A1 | COMPOSITIONS AND METHODS FOR OCULAR DELIVERY OF A THERAPEUTIC AGENT | TRUSTEES OF TUFTS COLLEGE (US) | 2017-06-22 | — | — | US | claimed |
| US-20150037422-A1 | COMPOSITIONS AND METHODS FOR OCULAR DELIVERY OF A THERAPEUTIC AGENT | TUFTS COLLEGE (US) | 2015-02-05 | — | — | US | claimed |
| EP-2817031-A1 | COMPOSITIONS AND METHODS FOR OCULAR DELIVERY OF A THERAPEUTIC AGENT | Trustees Of Tufts College (US) | 2014-12-31 | — | — | EP | claimed |
| WO-2013126799-A1 | COMPOSITIONS AND METHODS FOR OCULAR DELIVERY OF A THERAPEUTIC AGENT | TRUSTEES OF TUFTS COLLEGE (US) | 2013-08-29 | — | — | WO | claimed |
| US-20260091079-A1 | SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260048039-A1 | OCULAR FORMULATIONS FOR DRUG-DELIVERY AND PROTECTION OF THE ANTERIOR SEGMENT OF THE EYE | PANOPTICA INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4685488-A1 | METHOD FOR RENAL CANCER DETECTION | IMBA-Institut für Molekulare Biotechnologie GmbH (AT) | 2026-01-28 | — | — | EP | disclosed |
| US-20250346906-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE | ALNYLAM PHARMACEUTICALS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12351822-B2 | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-07-08 | — | — | US | disclosed |
| US-12285459-B2 | Saposin-A derived peptides and uses thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-04-29 | — | — | US | disclosed |
| WO-2025058571-A1 | POLYMER COMPOSITION COMPRISING A THERMOGELLING POLYMER AND A TYROSINE KINASE INHIBITOR, AND RELATED METHODS THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2025-03-20 | — | — | WO | disclosed |
| CN-114945378-B | Feeder-based and feeder-free stem cell culture systems for stratified epithelial stem cells and related uses thereof | 休斯敦大学体系 | 2024-11-19 | — | — | CN | disclosed |
| EP-1337521-B1 | SALTS OF AN ISOTHIAZOLE-4-CARBOXAMIDE AND THEIR USE AS ANTI-HYPERPROLIFERATION AGENTS | PFIZER PROD INC (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20050245456-A1 | Combination therapy to prevent and treat diarrhea induced by cancer treatment | PFIZER INC | 2005-11-03 | — | — | US | disclosed |
| WO-2005094830-A1 | COMBINATIONS OF SIGNAL TRANSDUCTION INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222163-A1 | Combinations of signal transduction inhibitors | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| US-6831091-B2 | Anticancer agents | PFIZER INC. | 2004-12-14 | — | — | US | disclosed |
| EP-1337521-A1 | SALTS OF AN ISOTHIAZOLE-4-CARBOXAMIDE AND THEIR USE AS ANTI-HYPERPROLIFERATION AGENTS | Pfizer Products Inc. (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20020151573-A1 | Salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide and method of production | PFIZER INC. | 2002-10-17 | — | — | US | disclosed |
| WO-2002044158-A1 | SALTS OF A ISOTHIAZOLE-4-CARBOXAMIDE AND THEIR USE AS ANTI-HYPERPROLIFERATION AGENTS | PFIZER PRODUCTS INC. (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151573-A1 | Salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide and method of production | CPS1, FH, CS | KDR 2187/4885PDGFRB 2017/4885FLT1 930/4885 |
| US-20260091079-A1 | SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF | PSAP, VEGFA, ENPEP | KDR 41/4885PDGFRB 254/4885FLT1 28/4885 |
| US-20250346906-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE | CD274, PDCD1LG2, PDCD4 | KDR 2093/4885PDGFRB 1936/4885FLT1 3736/4885 |
| US-20260048039-A1 | OCULAR FORMULATIONS FOR DRUG-DELIVERY AND PROTECTION OF THE ANTERIOR SEGMENT OF THE EYE | VEGFA, PROC, NNT | KDR 7/4885PDGFRB 692/4885FLT1 14/4885 |
| US-20050222163-A1 | Combinations of signal transduction inhibitors | CDK4, CDK3, CDK2 | KDR 446/4885PDGFRB 205/4885FLT1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.